Harris Technology receives top Amazon ranking as earnings continue to grow

|

Published 16-JUL-2020 09:57 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in Harris Technology Group Limited (ASX:HT8) have rallied strongly in the last three months with a key driver being the group’s establishment of a new line of protective hygiene products known as ‘Pro-Hygiene’.

Providing further momentum was a profit upgrade in June, but the company has received positive news on another front.

Management recently noted that Harris Technology had been rated as the top-ranked market place seller on Amazon Australia by independent US market research firm Marketplace Pulse.

The ranking is based on customer feedback following purchases on the Amazon Australia platform.

Commenting on this achievement, chief executive Garrison Huang said, “We are delighted to achieve the top Amazon Australia seller ranking, and are grateful for all the customer reviews and feedback received.

‘’We have been able to take advantage of Amazon Australia’s strong logistic and marketing power to grow our footprints on Amazon.

“Our strategy of working in partnership with the major e-commerce platforms is certainly contributing to our bottom line, with online sales growing substantially over the past year.

‘’We are continuously working closely with platforms such as Amazon, Kogan, Catch and eBay to complement the product offerings by leveraging HT’s expertise and knowledge in IT/CE products.”

These positive developments have underpinned a significant financial turnaround in fiscal 2020 as Harris delivered an annual net profit before tax in excess of $1.1 million (unaudited), compared to the previous year’s $732,000 loss.

Further profit growth in fiscal 2021

Management is expecting another year of ‘’exceptional’’ growth in fiscal 2021.

Given the expansion in the company’s product range, as well as increasing consumer and commercial demand for these types of products, particularly as regions experience second waves of COVID, Harris could experience significant sales growth.

The company has recently expanded product coverage from the existing range of face masks, hand sanitisers, alcohol wipes.

Harris has co-developed a foot-operated hand sanitiser dispenser which ensures non-contact dispensing.

The first trial order of 500 pcs is now in production.

There is also a shipment of 1000pc of non-touch infrared thermometers in transit to arrive at the end of July.

Sales of Pro-Hygiene PPE products have exceeded $1.4 million since launching.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X